Abstract
Skin is a more permeable organ than is commonly believed. Despite the effective barrier that it provides to protect the body against the invasion of microorganisms or the loss of water, it can allow permeation of drugs from topically applied creams and ointments (Scheuplein and Blank 1971) in quantities sufficient to produce systemic actions. Until recently such actions have usually been a cause for concern; for example, topical steroids valuable in dermatology are capable of disturbing the pituitary adrenal axis (Van Scott and Yu 1980). More recently, however, the transdermal route for administration of drugs to the systemic circulation has become a part of therapeutics. That development is attributable in large part to the advent of dosage forms capable of overcoming what Wepierre and Marty (1979) described as the chief obstacle to transdermal drug delivery: variability in drug absorption through skin, resulting in lack of precision regarding the real dose absorbed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Ausman RK, Caballero GA, Quebbeman E, Ausman DC (1982) Long-term ambulatory, continuous intravenous infusion of 5-fluorouracil for the treatment of metastatic adenocarcinoma in the liver. Wis Med J 81:25–28
Boekhorst JC, van Tol RGL (1985) Catapres transdermal therapeutic system (TTS) for long-term treatment of hypertension. In: Weber MA, Drayer JIM, Kollach R (eds) Low dose oral and transdermal therapy of hypertension. Steinkopff, Darmstadt, pp 106–110
Brand JJ, Whittingham P (1970) Intramuscular hyoscine in control of motion sickness. Lancet 2:232–235
Breimer DD, de Leede LGJ, de Boer AG (1985) Rate-controlled rectal drug delivery. In: Prescott LF, Nimmo WS (eds) Rate control in drug therapy. Churchill Livingstone, Edinburgh, pp 54–64
Dictionnaire Vidal, 62nd edn. (1986) OVP, Paris, p 1230
Eckenhoff B, Yum SI (1981) The osmotic pump: novel research tool for optimizing drug regimens. Biomaterials 2:89–97
Gérardin A, Gaudry D, Moppert J, Theobald W, Fankhauser P (1985) Glycerol trinitrate (nitroglycerin) plasma concentrations achieved after application of transdermal therapeutic systems to healthy volunteers. Arzneimittelforschung 35:530–532
Good WR, Powers MS, Campbell P, Schenkel L (1985) A new transdermal delivery system for estradiol. J Control Rel 2:89–97
Graybiel A, Knepton J, Shaw J (1976) Prevention of experimental motion sickness by scopolamine absorbed through the skin. Aviat Space Environ Med 47:1096–1100
Heindl I, Lorenz D, Siebers S, Blumberger W (1977) Klinische Prüfung des neuen perkutan wirksamen Antirheumatikums Etofenamat: Zusammenfassender Bericht. Arzneimittelforschung 27:1357–1363
Imhof PR (1985) Anti-anginal therapy with transdermal nitroglycerin. In: Prescott LF, Nimmo WS (eds) Rate control in drug therapy. Churchill Livingstone, Edinburgh, pp 201–214
Lawson AAH (1985) Clinical and pharmacological studies with transdermal Clonidine. In: Prescott LF, Nimmo WS (eds) Rate control in drug therapy. Churchill Livingstone, Edinburgh, pp 215–219
Lyrenäs S, Carlström K, Backström T, Von Schoultz B (1981) A comparison of serum oestrogen levels after percutaneous and oral administration of oestradiol-17β. Br J Obstet Gynecol 88:181–187
McCauley ME, Royal JW, Shaw JE, Schmitt LG (1979) Effect of transdermally administered scopolamine in preventing motion sickness. Aviat Space Environ Med 50:1108–1111
Mroczek WJ, Ulrych M, Yoder S (1982) Weekly transdermal Clonidine administration in hypertensive patients. Clin Pharmacol Ther 31:252
Physicians’ Desk Reference, 41sh edn. (1987) Medical Economics Company, Oradell pp 1177–1178, 1521, 1726, 2104, 1203–1206, 865–866
Place VA (1981) Transdermal therapeutic system for nitroglycerin: bioavailability, hemodynamic and clinical data. Seminar on transdermal therapeutic system: a major advance in angina prophylaxis. Presented in conjunction with the 16th American Society of Hospital Pharmacists Midyear Clinical Meeting, 6 December 1981, New Orleans
Place VA, Powers M, Darley PE, Schenkel L, Good WR (1985) A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal women. Am J Obstet Gynecol 152:1092–1099
Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA (1985) Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 152:1099–1106
Scheuplein RJ, Blank IH (1971) Permeability of the skin. Physiol Rev 51:702–747
Schmitt LG, Shaw JE, Carpenter PF, Chandrasekaran SK (1981) Comparison of transdermal and intravenous administration of scopolamine. Clin Pharmacol Ther 29:282
Shaw JE (1981) Development of the transdermal therapeutic system. Seminar on transdermal therapeutic system: a major advance in angina prophylaxis. Presented in conjunction with the 16th American Society of Hospital Pharmacists Midyear Clinical Meeting, 6 December 1981, New Orleans
Shaw JE (1984) Pharmacokinetics of nitroglycerin and Clonidine delivered by the transdermal route. Am Heart J 108:217–223
Shaw J, Urquhart J (1980) Programmed, systemic drug delivery by the transdermal route. Trends Pharmacol Sci 1:208–211
Tattersall AB, Bridgmen KM, Carr M (1985) Retrospective post-marketing surveillance of Transiderm-nitro 5 in general practice in the United Kingdom. J Int Med Res 13:222–228
Theeuwes F (1981) Drug delivery systems. Pharmacol Ther 13:149–191
Van Scott E, Yu RJ (1980) Drugs in dermatologic therapy. In: Modell W (ed) Drugs of choice: nineteen eighty to nineteen eighty-one. Mosby, St Louis, pp 681–694
Wepierre J, Marty JP (1979) Percutaneous absorption of drugs. Trends Pharmacol Sci 1:23–26
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Shaw, J.E., Chandrasekaran, S.K. (1989). Skin as a Mode for Systemic Drug Administration. In: Greaves, M.W., Shuster, S. (eds) Pharmacology of the Skin II. Handbook of Experimental Pharmacology, vol 87 / 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74054-1_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-74054-1_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74056-5
Online ISBN: 978-3-642-74054-1
eBook Packages: Springer Book Archive